Effect of Greenshell
Biomarker
Green-lipped mussel
Greenshell mussel
Inflammation
Osteoarthritis
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
28 Jul 2021
28 Jul 2021
Historique:
received:
02
09
2020
accepted:
21
07
2021
entrez:
29
7
2021
pubmed:
30
7
2021
medline:
31
7
2021
Statut:
epublish
Résumé
New Zealand Greenshell™ mussels (GSM; Perna canaliculus) have recently been shown to decrease cartilage degradation in a rat model of induced metabolic osteoarthritis (MetOA). However, this effect has not been investigated in human subjects. This study aims to determine the effect of GSM powder on biomarkers of cartilage metabolism, bone resorption, and inflammation in New Zealand healthy overweight/obese postmenopausal women who are at early stage or at high risk of OA. Fifty overweight or obese (BMI 25-35 kg/m This trial will be the first to explore the effects of whole meat GSM powder on cartilage turnover, bone resorption, and inflammation biomarkers in overweight/obese postmenopausal women. The results from this trial will provide evidence on the efficacy of GSM in the prevention of OA. Australian New Zealand Clinical Trials Registry (ANZCTR) ACTRN12620000413921p . Registration on 27 March 2020.
Sections du résumé
BACKGROUND
BACKGROUND
New Zealand Greenshell™ mussels (GSM; Perna canaliculus) have recently been shown to decrease cartilage degradation in a rat model of induced metabolic osteoarthritis (MetOA). However, this effect has not been investigated in human subjects. This study aims to determine the effect of GSM powder on biomarkers of cartilage metabolism, bone resorption, and inflammation in New Zealand healthy overweight/obese postmenopausal women who are at early stage or at high risk of OA.
METHOD
METHODS
Fifty overweight or obese (BMI 25-35 kg/m
DISCUSSION
CONCLUSIONS
This trial will be the first to explore the effects of whole meat GSM powder on cartilage turnover, bone resorption, and inflammation biomarkers in overweight/obese postmenopausal women. The results from this trial will provide evidence on the efficacy of GSM in the prevention of OA.
TRIAL REGISTRATION
BACKGROUND
Australian New Zealand Clinical Trials Registry (ANZCTR) ACTRN12620000413921p . Registration on 27 March 2020.
Identifiants
pubmed: 34321048
doi: 10.1186/s13063-021-05473-5
pii: 10.1186/s13063-021-05473-5
pmc: PMC8317363
doi:
Substances chimiques
Biomarkers
0
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
498Informations de copyright
© 2021. The Author(s).
Références
Drugs Aging. 2015 Mar;32(3):179-87
pubmed: 25701074
Obes Rev. 2015 Dec;16(12):1081-93
pubmed: 26395622
J Orthop Sports Phys Ther. 1998 Aug;28(2):88-96
pubmed: 9699158
N Engl J Med. 2005 Mar 10;352(10):1011-23
pubmed: 15758012
Osteoarthritis Cartilage. 2011 Jan;19(1):37-43
pubmed: 21044695
Br J Sports Med. 2010 Aug;44(10):741-6
pubmed: 18981036
Osteoarthritis Cartilage. 2005 Sep;13(9):769-81
pubmed: 15978850
Arthritis Rheum. 2008 Jan;58(1):26-35
pubmed: 18163497
Nutrients. 2019 Jul 15;11(7):
pubmed: 31311115
Mayo Clin Proc. 2017 Oct;92(10):1552-1558
pubmed: 28982486
Inflammopharmacology. 2013 Feb;21(1):79-90
pubmed: 22821424
Epidemiology. 1999 Mar;10(2):161-6
pubmed: 10069252
Asia Pac J Clin Nutr. 2003;12(1):50-60
pubmed: 12737011
Br J Nutr. 2012 Sep 28;108(6):949-52
pubmed: 22214730
Eur J Gastroenterol Hepatol. 2003 Feb;15(2):173-8
pubmed: 12560762
Curr Rev Musculoskelet Med. 2013 Jun;6(2):182-7
pubmed: 23471773
Gerontologist. 2016 Apr;56 Suppl 2:S243-55
pubmed: 26994264
Inflammopharmacology. 2012 Apr;20(2):71-6
pubmed: 22366869
Joint Bone Spine. 2003 Aug;70(4):257-62
pubmed: 12951307
Proc Nutr Soc. 2005 May;64(2):163-9
pubmed: 15960861
Cytokine Growth Factor Rev. 2018 Dec;44:38-50
pubmed: 30340925
Bull World Health Organ. 2003;81(9):646-56
pubmed: 14710506